136 related articles for article (PubMed ID: 30953675)
1. Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer.
Márton É; Lukács J; Penyige A; Janka E; Hegedüs L; Soltész B; Méhes G; Póka R; Nagy B; Szilágyi M
J Biotechnol; 2019 May; 297():58-65. PubMed ID: 30953675
[TBL] [Abstract][Full Text] [Related]
2.
Wu L; Shang W; Zhao H; Rong G; Zhang Y; Xu T; Zhang J; Huang P; Wang F
Dis Markers; 2019; 2019():7541857. PubMed ID: 31467618
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
4. The Cell-Free Expression of MiR200 Family Members Correlates with Estrogen Sensitivity in Human Epithelial Ovarian Cells.
Márton É; Varga A; Széles L; Göczi L; Penyige A; Nagy B; Szilágyi M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419253
[TBL] [Abstract][Full Text] [Related]
5. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
6. A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer.
Zhu T; Gao W; Chen X; Zhang Y; Wu M; Zhang P; Wang S
Int J Gynecol Cancer; 2017 Jan; 27(1):3-10. PubMed ID: 27636713
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
8. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
9. The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients.
Zuberi M; Mir R; Khan I; Javid J; Guru SA; Bhat M; Sumi MP; Ahmad I; Masroor M; Yadav P; Vishnubhatla S; Saxena A
Microrna; 2020; 9(1):49-57. PubMed ID: 30799804
[TBL] [Abstract][Full Text] [Related]
10. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
[TBL] [Abstract][Full Text] [Related]
11. Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer.
Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
Adv Exp Med Biol; 2016; 924():3-8. PubMed ID: 27753009
[TBL] [Abstract][Full Text] [Related]
12. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma.
Guo F; Tian J; Lin Y; Jin Y; Wang L; Cui M
J Int Med Res; 2013 Oct; 41(5):1456-61. PubMed ID: 23963852
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer.
Gao YC; Wu J
Tumour Biol; 2015 Jun; 36(6):4843-50. PubMed ID: 25636451
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of circulating cell-free microRNAs in ovarian cancer.
Nakamura K; Sawada K; Yoshimura A; Kinose Y; Nakatsuka E; Kimura T
Mol Cancer; 2016 Jun; 15(1):48. PubMed ID: 27343009
[TBL] [Abstract][Full Text] [Related]
15. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
Zuberi M; Khan I; Gandhi G; Ray PC; Saxena A
Tumour Biol; 2016 Aug; 37(8):11259-66. PubMed ID: 26951510
[TBL] [Abstract][Full Text] [Related]
16. miRNA profile in ovarian cancer.
Ghafouri-Fard S; Shoorei H; Taheri M
Exp Mol Pathol; 2020 Apr; 113():104381. PubMed ID: 31954715
[TBL] [Abstract][Full Text] [Related]
17. Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer.
Su YY; Sun L; Guo ZR; Li JC; Bai TT; Cai XX; Li WH; Zhu YF
J Ovarian Res; 2019 Jan; 12(1):6. PubMed ID: 30670062
[TBL] [Abstract][Full Text] [Related]
18. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
19. Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of
Koukourakis MI; Kontomanolis E; Sotiropoulou M; Mitrakas A; Dafa E; Pouliliou S; Sivridis E; Giatromanolaki A
Anticancer Res; 2018 Oct; 38(10):5739-5745. PubMed ID: 30275195
[TBL] [Abstract][Full Text] [Related]
20. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
